Engineered Lysine Conjugated Immunoglobulins for Homogeneous ADCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for site-specific enzymatic modification of immunoglobulins to create conjugates with predictable conjugation rates and homogeneous drug-to-antibody ratios are limited due to the lack of specificity of microbial transglutaminase for lysine residues, leading to heterogeneous antibody-drug conjugate products.
Innovation Solution
Introducing engineered lysine residues into the immunoglobulin or its antigen-binding portion, allowing microbial transglutaminase to specifically conjugate with an acyl donor substrate containing a glutamine residue, resulting in site-specific and predictable incorporation of functional agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If microbial transglutaminase is used for site-specific enzymatic modification of immunoglobulins, then homogeneous antibody-drug conjugate products with defined DAR ratios can be produced, but the enzyme lacks specificity for lysine residues leading to heterogeneous products
Solution Approach 1:
The patent introduces a specific lysine residue at a defined position (e.g., K295 in the Fc region of IgG1) to create a localized conjugation site. This engineered lysine provides a specific target for microbial transglutaminase, ensuring that conjugation occurs at a predetermined location rather than randomly across multiple lysine residues, thereby achieving homogeneous ADC products with defined DAR ratios.
2Ease of manufacture
If lysine conjugation is performed using succinimide or isothiocyanate chemistry, then functional agents can be conjugated to immunoglobulins, but multiple lysines are modified resulting in heterogeneous mixtures with random drug positions
Solution Approach 1:
The patent performs preliminary engineering of the immunoglobulin by introducing a specific lysine residue at a predetermined position before the conjugation step. This pre-engineered lysine serves as a dedicated target site, ensuring that subsequent chemical conjugation occurs uniformly at this specific location rather than randomly across multiple lysine residues, thereby achieving homogeneous ADC products while maintaining manufacturing simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the generation of conjugated immunoglobulins with consistent drug-to-antibody ratios, enhancing the therapeutic index and stability of antibody-drug conjugates by ensuring precise and homogeneous conjugation.
Implementation Method 1
microbial transglutaminase that catalyze the formation of a stable isopeptide bond between the γ-carboxyamide group (acyl donor) of a glutamine and the ε-amino group (acyl acceptor) of a lysine
Implementation Method 2
catalyze the formation of a stable isopeptide bond between the γ-carboxyamide group (acyl donor) of a glutamine and the ε-amino group (acyl acceptor) of a lysine
Data Source
AI summary
Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.